With the buyout of Sitari Pharmaceuticals, Glaxosmithkline becomes only the second major drug maker to have an interest in coeliac disease.
Deal is the fifth largest robotics surgery purchase ever, and the second big move from Stryker.
Having succeeded with cystic fibrosis Vertex is now chasing a cure for type 1 diabetes.
Spending $250m on Modis gives Zogenix a new rare disease niche, but the timing and the target both look odd.
Ablation company takes on a new tech, and responsibility for an expensive clinical trial.
Vascular robotics is growing fast and Corindus is the leader here, but Healthineers will need an aggressive sales plan.
Bayer has responded to its current woes by going all in on cell therapy – a move that, even if successful, will take a long time to pay off.
Using EvaluatePharma data Vantage explored investment trends in biopharma and medtech, sales per employee at big drug makers, and the declining number of late-stage…
Continued interest in the Sting pathway might come as a surprise, though secrecy suggests that asset prices are failing.